Wendy Clarke

Biochemistry, Genetics and Molecular Biology · Life Sciences

14h-index1.1kcitations29works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Receptor Mechanisms and Signaling(6), Neuropeptides and Animal Physiology(4), Wnt/β-catenin signaling in development and cancer(4), PI3K/AKT/mTOR signaling in cancer(4), Cholinesterase and Neurodegenerative Diseases(4)

Publications29 total

My video journey: The work of Wendy Clarke
Moving Image Review & Art Journal (MIRAJ)·2024
Discovery of 2-(Anilino)pyrimidine-4-carboxamides as Highly Potent, Selective, and Orally Active Glycogen Synthase Kinase-3 (GSK-3) Inhibitors
Journal of Medicinal Chemistry·2023· 17 citedOpen Access
Design, Structure–Activity Relationships, and In Vivo Evaluation of Potent and Brain-Penetrant Imidazo[1,2-<i>b</i>]pyridazines as Glycogen Synthase Kinase-3β (GSK-3β) Inhibitors
Journal of Medicinal Chemistry·2023· 28 citedOpen Access
Structure-Activity Relationship (SAR) Studies on Substituted 2-(Pyridin-2-ylamino)-N-(pyridin-3-yl)isonicotinamide as Highly Potent, Selective and Brain Penetrant Glycogen Synthase Kinase-3 (GSK-3) Inhibitors
SSRN Electronic Journal·2023Open Access
An amide-based sulfenamide prodrug of gamma secretase inhibitor BMS–708163 delivers parent drug from an oral conventional solid dosage form in male beagle dog
Bioorganic & Medicinal Chemistry Letters·2019· 10 cited
BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia
ACS Medicinal Chemistry Letters·2017· 13 citedOpen Access
Development of 4-Heteroarylamino-1′-azaspiro[oxazole-5,3′-bicyclo[2.2.2]octanes] as α7 Nicotinic Receptor Agonists
ACS Medicinal Chemistry Letters·2016· 12 citedOpen Access
Design and Synthesis of a New Series of 4-Heteroarylamino-1′-azaspiro[oxazole-5,3′-bicyclo[2.2.2]octanes as α7 Nicotinic Receptor Agonists. 1. Development of Pharmacophore and Early Structure–Activity Relationship
Journal of Medicinal Chemistry·2016· 18 citedOpen Access
Discovery of Isonicotinamides as Highly Selective, Brain Penetrable, and Orally Active Glycogen Synthase Kinase-3 Inhibitors
Journal of Medicinal Chemistry·2016· 68 citedOpen Access
Design and Synthesis of 4-Heteroaryl 1,2,3,4-Tetrahydroisoquinolines as Triple Reuptake Inhibitors
ACS Medicinal Chemistry Letters·2014· 17 citedOpen Access
Heterocyclic modification of a novel bicyclo[3.1.0]hexane NPY1 receptor antagonist
Bioorganic & Medicinal Chemistry Letters·2013· 2 citedOpen Access
Discovery of a Novel Class of Bicyclo[3.1.0]hexanylpiperazines as Noncompetitive Neuropeptide Y Y1 Antagonists
ACS Medicinal Chemistry Letters·2012· 2 citedOpen Access
P4‐020: Separation of Aβ Reduction from Notch Toxicity with Gamma Secretase Inhibitors in Rats
Alzheimer s & Dementia·2010· 3 cited
Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one
Bioorganic & Medicinal Chemistry Letters·2010· 17 citedOpen Access
MSO Chamber Players 1 'The Hall of Mirrors
2009
Discovery and Evaluation of 4-(2-(4-chloro-1<i>H</i>-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)pyridin-2(1<i>H</i>)-one (BMS-695735), an Orally Efficacious Inhibitor of Insulin-like Growth Factor-1 Receptor Kinase with Broad Spectrum in Vivo Antitumor Activity
Journal of Medicinal Chemistry·2008· 32 citedOpen Access
Synthesis and structure–activity relationship of imidazo(1,2-a)thieno(3,2-e)pyrazines as IKK-β inhibitors
Bioorganic & Medicinal Chemistry Letters·2007· 34 citedOpen Access
Synthesis and evaluation of 5,5-diphenylimidazolones as potent human neuropeptide Y5 receptor antagonists
Bioorganic & Medicinal Chemistry·2006· 23 cited
Discovery of a 1<i>H</i>-Benzoimidazol-2-yl)-1<i>H</i>-pyridin-2-one (BMS-536924) Inhibitor of Insulin-like Growth Factor I Receptor Kinase with in Vivo Antitumor Activity
Journal of Medicinal Chemistry·2005· 134 citedOpen Access
Neurochemical, pharmacokinetic, and behavioral effects of the novel selective serotonin reuptake inhibitor BMS-505130
Pharmacology Biochemistry and Behavior·2005· 23 cited
page 1 of 2Next →

Frequent Co-authors

John E. Macor(9), Richard E. Olson(6), Mark G. Saulnier(5), Kurt Zimmermann(5), Dolatrai M. Vyas(5), Guanglin Luo(5), Catherine R. Burton(5), John W. Russell(5), Nicholas J. Lodge(5), Kimberley A. Lentz(5), Robert Zaczek(5), Patrick Brassil(4), F. Christopher Zusi(4), Françis Beaulieu(4), David B. Frennesson(4), Carol Krause(4), Kevin Kish(4), H.A. Lewis(4), Gene M. Dubowchik(4), Graham S. Poindexter(4)